左右滑动，查看ESMO现场照片
✩ 本文仅供医疗卫生等专业人士参考
内容审核：nyh
项目审核：李淳
参考文献：
[1]Shen Cun Fang，et al. Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: A prospective, single-arm, phase II clinical trial.2024 ESMO. 1369P.
[2]中国临床肿瘤学会(CSCO) 中西医结合专家委员会.抗肿瘤药物引起骨髓抑制中西医结合诊治专家共识[J].临床肿瘤学杂志,2021,26(11):1020-1027.
[3]《中国肿瘤化疗相关骨髓抑制及临床管理现状调研报告（2023年）》.
[4]Epstein RS, Aapro MS, Basu Roy UK, et al. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. Adv Ther. 2020;37(8):3606-3618.
[5]Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019;30(10):1613-1621.
[6]Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020;8(2):e000847.
[7]Wang YS, et al. A phase II, Randomized Trial of Trilaciclib plus Chemotherapy and Tislelizumab as First-line Treatment for Advanced SqNSCLC. 2024 WCLC. P4.11E.05.